KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 2643 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial. PMID 41967349 · Eur J Cancer · 2026-Jun-03 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial. PMID 42295761 · JAMA Netw Open · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. PMID 42229584 · Ann Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial. PMID 42224659 · JAMA Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. PMID 42224490 · JAMA · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. PMID 42223137 · J Clin Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer. PMID 42219560 · Cancer Res Commun · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 11 Panel · risk visible
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial. PMID 42060297 · JAMA Oncol · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial. PMID 41837753 · Clin Cancer Res · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 5 Figure · 11 Panel · risk unclear
Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial. PMID 41711624 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors. PMID 41504634 · Clin Cancer Res · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 1 Panel · risk unclear
CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial. PMID 41352689 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 The record is a randomized controlled trial in human oncology (rectal cancer) evaluating a drug intervention (CapeOX vs capecitabine) with a primary time-to-event endpoint (3-year DFS). It reports definitive long-term results and is not an interim, subgroup, or safety-only analysis. Phase III is not explicitly stated but the trial is described as a definitive, multicenter, randomized controlled trial with a large sample size (n=505) and definitive primary endpoint, qualifying as a definitive phase trial under the criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group. PMID 41285272 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 4 Panel · risk unclear
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. PMID 42317205 · Hemasphere · 2026-Jun Meets all eligibility criteria: oncology, human, Phase III, randomized, drug intervention, time-to-event primary endpoint, original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 3 Panel · risk visible
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS). PMID 42308452 · JCO Glob Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. PMID 42306064 · Hemasphere · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 3 Figure · 11 Panel · risk unclear
Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First-line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non-comparative, Randomized Phase 2 Trial. PMID 42266185 · MedComm (2020) · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. PMID 42225101 · Lancet Oncol · 2026-Jun All required criteria (oncology, human, randomized, phase 3, drug intervention, time-to-event endpoint, original result) are explicitly established in the record.
H L S B
旧组与严格 v3 交集 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. PMID 42202490 · ESMO Open · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer. PMID 42187551 · NEJM Evid · 2026-Jun Meets all eligibility criteria: oncology RCT in humans, Phase III (implied by definitive adjuvant trial with survival endpoints), drug intervention, time-to-event efficacy endpoints reported, and original final results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III Database. PMID 42173719 · Clin Lung Cancer · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol. PMID 42125606 · ILIVER · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma. PMID 42108156 · Dig Liver Dis · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI). PMID 42107198 · Clin Lung Cancer · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung. PMID 42000139 · Lung Cancer · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial. PMID 41996761 · Lung Cancer · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma. PMID 41991383 · Urol Oncol · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial. PMID 41990300 · J Clin Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial. PMID 41896648 · Nat Med · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 41840238 · Nat Med · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 8 Panel · risk visible
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307. PMID 41811656 · Oncol Ther · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 6 Panel · risk visible
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. PMID 41739398 · Ann Surg Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. PMID 41720427 · Ann Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial. PMID 41690366 · J Thorac Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma. PMID 41688329 · Clin Colorectal Cancer · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. PMID 41687718 · Ann Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial. PMID 41621752 · J Thorac Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial. PMID 41571045 · Ann Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109. PMID 41535566 · Ann Surg Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 3 Figure · 8 Panel · risk unclear
High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. PMID 41454190 · Ann Surg Oncol · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 4 Figure · 12 Panel · risk visible
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2). PMID 41073155 · Int J Gynecol Cancer · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. PMID 42507968 · J Clin Oncol · 2026-Jul-27 The record describes a published, original, primary analysis of a phase III randomized trial in human oncology with a drug intervention and time-to-event efficacy endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX. PMID 42269244 · Eur J Cancer · 2026-Jul-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. PMID 42497381 · J Clin Oncol · 2026-Jul-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial. PMID 42492015 · J Clin Oncol · 2026-Jul-23 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. PMID 42485627 · N Engl J Med · 2026-Jul-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials. PMID 42485700 · ESMO Open · 2026-Jul-22 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. PMID 42483812 · Biomol Biomed · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer. PMID 42481259 · Farm Hosp · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study. PMID 42480197 · ESMO Open · 2026-Jul-21 The record explicitly describes a Phase III randomized trial with a drug-containing intervention and primary time-to-event efficacy endpoints (PFS, OS) with hazard ratios and survival rates, meeting all eligibility criteria.
H B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 4 Figure · 7 Panel · risk visible